Ben Doak

Ben Doak is the Head of Innovative Treatments at NHS England.

Ben’s primary role is to fulfil NHS England’s commissioning responsibility to ensure that services are in place so patients can benefit from licensed ATMPs recommended by NICE (the National Institute of Health and Care Excellence) in the NHS in England.

Ben has worked in innovation through various roles in his career, including working with surgical innovations, overseeing the placement of innovations in treatment pathways through NICE clinical guidelines and streamlining commercial activity for new technologies in NHS England’s Commercial Medicines Directorate.

Since commencing his current role in 2020, Ben has overseen the expansion of CAR-T services in England as well as supporting access to ATMPs such as Zolgensma for spinal muscular atrophy, Libmeldy for metachromatic leukodystrophy and Upstaza for AADC deficiency. He maintains an active interest in horizon scanning of ATMPs and other innovative treatments.